Nathaniel P. Katz, M.D., is widely regarded as a global expert in post herpetic neuralgia (PHN) pain management and President and CEO of Analgesic Solutions, a research, education, and consulting firm exclusively focused on pain therapeutics. Dr. Katz is also Adjunct Assistant Professor of Anesthesia at Tufts University School of Medicine. After completing his neurology residency at Tufts-New England Medical Center, he entered a pain management fellowship in the Department of Anesthesia at Brigham & Women’s Hospital in 1990 and was later appointed staff neurologist in the Pain Management Center. Dr. Katz subsequently founded the Pain & Symptom Management Program at Dana-Farber Cancer Institute and the Pain Trials Center at Brigham & Women’s Hospital. Dr. Katz also has previously served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division at the FDA. Dr. Katz is active in shaping public policy to reduce prescription opioid fraud and abuse, having served as a consultant to the Office of National Drug Policy and other government agencies.
Dr. Katz has completed numerous clinical trials of treatments for pain, both industry-initiated and investigator-initiated, involving pharmaceuticals, non-pharmaceutical analgesics, and devices, and has also conducted studies related to opioids, pain, and addiction. He has over 60 publications in peer-reviewed journals and numerous presentations at scientific congresses. He has served as an Associate Editor at the Clinical Journal of Pain and Associate Editor (Pain) for the Encyclopedia of Neurological Sciences, and has overseen many local and national educational programs on pain management.